Stay updated on Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial page.

Latest updates to the Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial page
- Check3 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2 on the site.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedRevision indicator updated from v3.4.3 to v3.5.0. No study content or eligibility details appear to be affected.SummaryDifference0.0%

- Check45 days agoChange DetectedRevision: v3.4.3 is now shown, replacing the previous Revision: v3.4.2.SummaryDifference0.0%

- Check67 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2 is reflected on the page. This is a technical update with no substantive changes to study data or displayed information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check75 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1.SummaryDifference0.0%

- Check96 days agoChange DetectedThe page now shows Revision: v3.3.4, replacing the previous Revision: v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial page.